<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:019c2f4b-9b36-71fb-9ee6-c002abddfc8e,g:00b25ae2-26a4-499c-90c9-fba79313dec7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abus="http://www.tekmirapharm.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.tekmirapharm.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abus-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.tekmirapharm.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.tekmirapharm.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.tekmirapharm.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementofStockholdersEquity" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementofStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statement of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.tekmirapharm.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.tekmirapharm.com/role/Organization">
        <link:definition>9952156 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Significantaccountingpolicies" roleURI="http://www.tekmirapharm.com/role/Significantaccountingpolicies">
        <link:definition>9952157 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://www.tekmirapharm.com/role/Fairvaluemeasurements">
        <link:definition>9952158 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investmentsinmarketablesecurities" roleURI="http://www.tekmirapharm.com/role/Investmentsinmarketablesecurities">
        <link:definition>9952159 - Disclosure - Investments in marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevant" roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevant">
        <link:definition>9952160 - Disclosure - Investment in Genevant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.tekmirapharm.com/role/Leases">
        <link:definition>9952161 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyandequipment" roleURI="http://www.tekmirapharm.com/role/Propertyandequipment">
        <link:definition>9952162 - Disclosure - Property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountspayableandaccruedliabilities" roleURI="http://www.tekmirapharm.com/role/Accountspayableandaccruedliabilities">
        <link:definition>9952163 - Disclosure - Accounts payable and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Saleoffutureroyalties" roleURI="http://www.tekmirapharm.com/role/Saleoffutureroyalties">
        <link:definition>9952164 - Disclosure - Sale of future royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingenciesandcommitments" roleURI="http://www.tekmirapharm.com/role/Contingenciesandcommitments">
        <link:definition>9952165 - Disclosure - Contingencies and commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Collaborationsandroyaltyentitlements" roleURI="http://www.tekmirapharm.com/role/Collaborationsandroyaltyentitlements">
        <link:definition>9952166 - Disclosure - Collaborations and royalty entitlements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Shareholdersequity" roleURI="http://www.tekmirapharm.com/role/Shareholdersequity">
        <link:definition>9952167 - Disclosure - Shareholders&#8217; equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockbasedcompensation" roleURI="http://www.tekmirapharm.com/role/Stockbasedcompensation">
        <link:definition>9952168 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.tekmirapharm.com/role/SegmentReporting">
        <link:definition>9952169 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.tekmirapharm.com/role/Incometaxes">
        <link:definition>9952170 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.tekmirapharm.com/role/Restructuring">
        <link:definition>9952171 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Relatedpartytransactions" roleURI="http://www.tekmirapharm.com/role/Relatedpartytransactions">
        <link:definition>9952172 - Disclosure - Related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.tekmirapharm.com/role/SubsequentEvents">
        <link:definition>9952173 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesPolicies" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesPolicies">
        <link:definition>9955511 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesTables" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesTables">
        <link:definition>9955512 - Disclosure - Significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsTables">
        <link:definition>9955513 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesTables" roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesTables">
        <link:definition>9955514 - Disclosure - Investments in marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.tekmirapharm.com/role/LeasesTables">
        <link:definition>9955515 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentTables" roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentTables">
        <link:definition>9955516 - Disclosure - Property and equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesTables" roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesTables">
        <link:definition>9955517 - Disclosure - Accounts payable and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesTables" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesTables">
        <link:definition>9955518 - Disclosure - Sale of future royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsTables" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsTables">
        <link:definition>9955519 - Disclosure - Collaborations and royalty entitlements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationTables" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationTables">
        <link:definition>9955520 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.tekmirapharm.com/role/SegmentReportingTables">
        <link:definition>9955521 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.tekmirapharm.com/role/IncometaxesTables">
        <link:definition>9955522 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.tekmirapharm.com/role/RestructuringTables">
        <link:definition>9955523 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.tekmirapharm.com/role/OrganizationDetails">
        <link:definition>9955524 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesNarrativeDetails">
        <link:definition>9955525 - Disclosure - Significant accounting policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesEstimatedusefullivesofpropertyandequipmentDetails">
        <link:definition>9955526 - Disclosure - Significant accounting policies - Estimated useful lives of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails" roleURI="http://www.tekmirapharm.com/role/SignificantaccountingpoliciesComputationofbasicanddilutednetincomelosspercommonshareDetails">
        <link:definition>9955527 - Disclosure - Significant accounting policies - Computation of basic and diluted net income (loss) per common share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsValuationDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsValuationDetails">
        <link:definition>9955528 - Disclosure - Fair value measurements - Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsNarrativeDetails">
        <link:definition>9955529 - Disclosure - Fair value measurements&#160; - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsAssetsandliabilitiesmeasuredatfairvalueonrecurringbasisDetails">
        <link:definition>9955530 - Disclosure - Fair value measurements&#160; - Assets and liabilities measured at fair value on recurring basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails" roleURI="http://www.tekmirapharm.com/role/FairvaluemeasurementsChangesinfairvalueofcontingentconsiderationDetails">
        <link:definition>9955531 - Disclosure - Fair value measurements&#160;- Changes in fair value of contingent consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesDetails" roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesDetails">
        <link:definition>9955532 - Disclosure - Investments in marketable securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinmarketablesecuritiesnarrativeDetails" roleURI="http://www.tekmirapharm.com/role/InvestmentsinmarketablesecuritiesnarrativeDetails">
        <link:definition>9955533 - Disclosure - Investments in marketable securities - narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentinGenevantDetails" roleURI="http://www.tekmirapharm.com/role/InvestmentinGenevantDetails">
        <link:definition>9955534 - Disclosure - Investment in Genevant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/LeasesNarrativeDetails">
        <link:definition>9955535 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasecostDetails" roleURI="http://www.tekmirapharm.com/role/LeasesLeasecostDetails">
        <link:definition>9955536 - Disclosure - Leases - Lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofleaseliabilityDetails" roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails">
        <link:definition>9955537 - Disclosure - Leases - Maturity of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofleaseliabilityDetails_1" roleURI="http://www.tekmirapharm.com/role/LeasesMaturityofleaseliabilityDetails_1">
        <link:definition>9955537 - Disclosure - Leases - Maturity of lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentDetails" roleURI="http://www.tekmirapharm.com/role/PropertyandequipmentDetails">
        <link:definition>9955538 - Disclosure - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesDetails" roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesDetails">
        <link:definition>9955539 - Disclosure - Accounts payable and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandaccruedliabilitiesRestructuringDetails" roleURI="http://www.tekmirapharm.com/role/AccountspayableandaccruedliabilitiesRestructuringDetails">
        <link:definition>9955540 - Disclosure - Accounts payable and accrued liabilities - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesNarrativeDetails">
        <link:definition>9955541 - Disclosure - Sale of future royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleoffutureroyaltiesActivityDetails" roleURI="http://www.tekmirapharm.com/role/SaleoffutureroyaltiesActivityDetails">
        <link:definition>9955542 - Disclosure - Sale of future royalties - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandcommitmentsDetails" roleURI="http://www.tekmirapharm.com/role/ContingenciesandcommitmentsDetails">
        <link:definition>9955543 - Disclosure - Contingencies and commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsNarrativeDetails">
        <link:definition>9955544 - Disclosure - Collaborations and royalty entitlements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationsandroyaltyentitlementsSummaryofrevenuesDetails" roleURI="http://www.tekmirapharm.com/role/CollaborationsandroyaltyentitlementsSummaryofrevenuesDetails">
        <link:definition>9955545 - Disclosure - Collaborations and royalty entitlements - Summary of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersequityDetails" roleURI="http://www.tekmirapharm.com/role/ShareholdersequityDetails">
        <link:definition>9955546 - Disclosure - Shareholders&#8217; equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationNarrativeDetails">
        <link:definition>9955547 - Disclosure - Stock-based compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationActivityrelatedtostockoptionsDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationActivityrelatedtostockoptionsDetails">
        <link:definition>9955548 - Disclosure - Stock-based compensation - Activity related to stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockoptionsoutstandingundertheArbutusPlanDetails">
        <link:definition>9955549 - Disclosure - Stock-based compensation - Stock options outstanding under the Arbutus Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationValuationassumptionsforstockoptionsundertheArbutusPlanDetails">
        <link:definition>9955550 - Disclosure - Stock-based compensation - Valuation assumptions for stock options under the Arbutus Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationRestrictedStockUnitsDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationRestrictedStockUnitsDetails">
        <link:definition>9955551 - Disclosure - Stock-based compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedcompensationStockbasedcompensationexpenseDetails" roleURI="http://www.tekmirapharm.com/role/StockbasedcompensationStockbasedcompensationexpenseDetails">
        <link:definition>9955552 - Disclosure - Stock-based compensation - Stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingDetails" roleURI="http://www.tekmirapharm.com/role/SegmentReportingDetails">
        <link:definition>9955553 - Disclosure - Segment Reporting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesProvisionBenefitDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesProvisionBenefitDetails">
        <link:definition>9955554 - Disclosure - Income taxes - Provision/Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncomeTaxRateReconciliationPostASU202309UpdateDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesIncomeTaxRateReconciliationPostASU202309UpdateDetails">
        <link:definition>9955555 - Disclosure - Income taxes - Income Tax Rate Reconciliation, Post ASU 2023-09 Update (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesIncomeTaxRateReconciliationPriorPeriodDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesIncomeTaxRateReconciliationPriorPeriodDetails">
        <link:definition>9955556 - Disclosure - Income taxes - Income Tax Rate Reconciliation, Prior Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesNarrativeDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesNarrativeDetails">
        <link:definition>9955557 - Disclosure - Income taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDeferredtaxassetsandliabilitiesDetails" roleURI="http://www.tekmirapharm.com/role/IncometaxesDeferredtaxassetsandliabilitiesDetails">
        <link:definition>9955558 - Disclosure - Income taxes - Deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringDetails" roleURI="http://www.tekmirapharm.com/role/RestructuringDetails">
        <link:definition>9955559 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedpartytransactionsDetails" roleURI="http://www.tekmirapharm.com/role/RelatedpartytransactionsDetails">
        <link:definition>9955560 - Disclosure - Related party transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.tekmirapharm.com/role/SubsequentEventsDetails">
        <link:definition>9955561 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abus_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" abstract="false" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_CollaborationAndContractsMember" abstract="true" name="CollaborationAndContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NonCashRoyaltyMember" abstract="true" name="NonCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_WeightedAverageNumberOfCommonSharesAbstract" abstract="true" name="WeightedAverageNumberOfCommonSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodSharesNewIssuesOpenMarketSaleAgreement" abstract="false" name="StockIssuedDuringPeriodSharesNewIssuesOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="abus_StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement" abstract="false" name="StockIssuedDuringPeriodValueNewIssuesOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement" abstract="false" name="ProceedsFromIssuanceOfCommonStockOpenMarketSaleAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" abstract="false" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" abstract="false" name="LiabilitiesRelatedToSaleOfFutureRoyaltiesRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="abus_OneTimeUpfrontCashPaymentMember" abstract="true" name="OneTimeUpfrontCashPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_GenevantSciencesCorporationMember" abstract="true" name="GenevantSciencesCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_DirectorsAndExecutivesMember" abstract="true" name="DirectorsAndExecutivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LaboratoryEquipmentMember" abstract="false" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ProbabilityOfSucessMember" abstract="true" name="ProbabilityOfSucessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EnantigenTherapeuticsIncMember" abstract="true" name="EnantigenTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_FairValueLiabilitiesMeasuredonRecurringBasisRollForward" abstract="true" name="FairValueLiabilitiesMeasuredonRecurringBasisRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_USGovernmentBondsMember" abstract="true" name="USGovernmentBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_USCorporateBondsMember" abstract="true" name="USCorporateBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SubLicensingRevenuePercentage" abstract="false" name="SubLicensingRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_BonaFideCollaborationPercentage" abstract="false" name="BonaFideCollaborationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" abstract="true" name="CorporateHeadquartersLocated701VeteransCircleWarminsterPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_FixedLeaseCost" abstract="false" name="FixedLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AccruedPayrollCurrent" abstract="false" name="AccruedPayrollCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AccruedResearchandDevelopmentCurrent" abstract="false" name="AccruedResearchandDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RestructuringAndWorkforceReductionMember" abstract="true" name="RestructuringAndWorkforceReductionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_SeveranceAndEmployeeBenefitCostsAndLeaseExpensesMember" abstract="true" name="SeveranceAndEmployeeBenefitCostsAndLeaseExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OMERSMember" abstract="true" name="OMERSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OtherLiabilitiesDisclosureLineItems" abstract="true" name="OtherLiabilitiesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_RoyaltyPercentageofInterestSold" abstract="false" name="RoyaltyPercentageofInterestSold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" abstract="false" name="RoyaltyInterestSoldPercentageOfSalesAnnualRevenueThresholdOfHighestTier" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_GrossProceedsFromRoyaltyInterestSold" abstract="false" name="GrossProceedsFromRoyaltyInterestSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoyaltyInterestSoldMaximumRoyaltiesForBuyer" abstract="false" name="RoyaltyInterestSoldMaximumRoyaltiesForBuyer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoyaltyGuaranteesCommitmentsPercentage" abstract="false" name="RoyaltyGuaranteesCommitmentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_RoyaltyPayable" abstract="false" name="RoyaltyPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_TransactionCostsRelatedToSaleOfFutureRoyalties" abstract="false" name="TransactionCostsRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EffectiveAnnualInterestRateOfRoyaltyLiability" abstract="false" name="EffectiveAnnualInterestRateOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_RoyaltyInterestPercentInterest" abstract="false" name="RoyaltyInterestPercentInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_AnnualRevenueThreshold" abstract="false" name="AnnualRevenueThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LiabilityRelatedToFutureRoyaltiesRollForward" abstract="true" name="LiabilityRelatedToFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" abstract="false" name="LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ONPATTROGlobalNetSalesMember" abstract="true" name="ONPATTROGlobalNetSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsTable" abstract="true" name="ContingenciesandCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_BlumbergandDrexelMember" abstract="true" name="BlumbergandDrexelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ArbutusInc.Member" abstract="true" name="ArbutusInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EnantigenMember" abstract="false" name="EnantigenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_EnantigensSellingShareholdersMember" abstract="true" name="EnantigensSellingShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ContingenciesandCommitmentsLineItems" abstract="true" name="ContingenciesandCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" abstract="false" name="LicenseAgreementMaximumDevelopmentAndRegulatoryMilestonePaymentsPerRoyalty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_BarinthusMember" abstract="true" name="BarinthusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OnpattroCashRoyaltyMember" abstract="true" name="OnpattroCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_QiluPharmaceuticalCoLTDMember" abstract="true" name="QiluPharmaceuticalCoLTDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OnpattroNonCashRoyaltyMember" abstract="true" name="OnpattroNonCashRoyaltyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_LicenseAgreementMilestonePaymentMaximum" abstract="false" name="LicenseAgreementMilestonePaymentMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_PremiumonClosingStockPrice" abstract="false" name="PremiumonClosingStockPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_PercentOfCostsRelatedToCollaboration" abstract="false" name="PercentOfCostsRelatedToCollaboration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_AlnylamEntitlements" abstract="false" name="AlnylamEntitlements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="abus_EquityMethodInvestmentPercentageOfRevenueEntitled" abstract="false" name="EquityMethodInvestmentPercentageOfRevenueEntitled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_OtherMilestonesAndRoyaltyPaymentsMember" abstract="true" name="OtherMilestonesAndRoyaltyPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Dec2024ProspectusSupplementMember" abstract="true" name="Dec2024ProspectusSupplementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_OpenMarketSaleAgreementMember" abstract="true" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_RegistrationStatementAxis" abstract="true" name="RegistrationStatementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_RegistrationStatementDomain" abstract="true" name="RegistrationStatementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_Dec2024RegistrationStmtsMember" abstract="true" name="Dec2024RegistrationStmtsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_A2016And2011PlansMember" abstract="true" name="A2016And2011PlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_NaftzgerPlanMember" abstract="true" name="NaftzgerPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ArbutusPlansMember" abstract="true" name="ArbutusPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_CommonStockDiscountOnSharesPercentage" abstract="false" name="CommonStockDiscountOnSharesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="abus_VestedMember" abstract="true" name="VestedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ShareBasedCompensationExpenseAllocationIncomeStatementLocationAxis" abstract="true" name="ShareBasedCompensationExpenseAllocationIncomeStatementLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="abus_ShareBasedCompensationExpenseAllocationIncomeStatementLocationDomain" abstract="true" name="ShareBasedCompensationExpenseAllocationIncomeStatementLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ShareBasedCompensationExpenseAllocationResearchAndDevelopmentMember" abstract="true" name="ShareBasedCompensationExpenseAllocationResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ShareBasedCompensationExpenseAllocationGeneralAndAdministrativeExpenseMember" abstract="true" name="ShareBasedCompensationExpenseAllocationGeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ShareBasedCompensationExpenseAllocationRestructuringChargesMember" abstract="true" name="ShareBasedCompensationExpenseAllocationRestructuringChargesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ResearchAndDevelopmentEmployeeExpenseLabSuppliesAndOverhead" abstract="false" name="ResearchAndDevelopmentEmployeeExpenseLabSuppliesAndOverhead" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ImdusiranIMPROVEIIIIIIClinicalTrialsExpense" abstract="false" name="ImdusiranIMPROVEIIIIIIClinicalTrialsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_AB101001Phase1abClinicalTrialExpense" abstract="false" name="AB101001Phase1abClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_OtherSegmentExpense" abstract="false" name="OtherSegmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_SegmentNetLoss" abstract="false" name="SegmentNetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EffectiveIncomeTaxRateReconciliationTaxAbatementAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxAbatementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_EffectiveIncomeTaxRateReconciliationTaxAbatementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxAbatementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="abus_EffectiveIncomeTaxRateReconciliationPermanentAndOtherReconcilingItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentAndOtherReconcilingItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetBookAmortizationInExcessOfTax" abstract="false" name="DeferredTaxAssetBookAmortizationInExcessOfTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" abstract="false" name="DeferredTaxAssetRevenueRecognizedForTaxPurposesInExcessOfRevenueRecognizedForAccountingPurposes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" abstract="false" name="DeferredTaxAssetTaxValueInExcessOfAccountingValueInLeaseInducements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_DeferredTaxAssetsLiabilitiesGross" abstract="false" name="DeferredTaxAssetsLiabilitiesGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="abus_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_ModernaV.GenevantsAndArbutusLNPDeliveryTechnologyMember" abstract="true" name="ModernaV.GenevantsAndArbutusLNPDeliveryTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="abus_PercentOfLitigationSettlementToBeReceivedAfterCosts" abstract="false" name="PercentOfLitigationSettlementToBeReceivedAfterCosts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
